Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
The Medicines Company (the “Company”) today provided notice of a Make-Whole Fundamental Change to holders of its (i) 2.50% Convertible Senior Notes due 2022 (the “2022 Notes”), (ii) 2.75...
NexPoint Residential Trust and Meritor Set to Join S&P SmallCap 600 PR Newswire NEW YORK, Dec. 30, 2019 NEW YORK, Dec. 30, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the...
SHAREHOLDER ALERT: WeissLaw LLP Investigates The Medicines Co. PR Newswire NEW YORK, Nov. 26, 2019 NEW YORK, Nov. 26, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of The Medicines Company PR Newswire NEW YORK, Nov. 25, 2019 NEW YORK, Nov. 25, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating...
(MDCO) Alert: Johnson Fistel Investigates Proposed Sale of The Medicines Company; Is $85 a Fair Price? PR Newswire SAN DIEGO, Nov. 25, 2019 SAN DIEGO, Nov. 25, 2019 /PRNewswire/ -- Shareholder...
- The Medicines Company to be acquired by Novartis AG for $85 per share in cash, representing 45% premium to its unaffected share price and a 57% premium to its unaffected one-week average price...
- Inclisiran achieved 50% LDL-C lowering with time-adjusted reductions of 45% sustained over 18 months of treatment in patients with heterozygous familial hypercholesterolemia (HeFH) - ORION-9...
- Inclisiran achieved 58% LDL-C lowering with time-adjusted reductions of 56% sustained over 18 months of treatment in patients with atherosclerotic cardiovascular disease (ASCVD) - ORION-10...
ORION-10 presentation on November 16 and ORION-9 presentation on November 18 Company also to sponsor educational sessions throughout AHA annual meeting Company to host investor conference call...
- Inclisiran’s pivotal Phase 3 LDL-C lowering clinical trials program successfully completed, and each study met all primary and secondary endpoints - Phase 3 data reinforced durable, potent...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
